FMC Crossroads is a medicare approved dialysis facility center in Augusta, Georgia and it has 17 dialysis stations. It is located in Columbia county at 1719 Magnolia Way, Augusta, GA, 30919. You can reach out to the office of FMC Crossroads at (706) 228-7253. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Crossroads has the following ownership type - Profit. It was first certified by medicare in September, 2009. The medicare id for this facility is 112819 and it accepts patients under medicare ESRD program.
Name | FMC Crossroads |
---|---|
Location | 1719 Magnolia Way, Augusta, Georgia |
No. of Dialysis Stations | 17 |
Medicare ID | 112819 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
1719 Magnolia Way, Augusta, Georgia, 30919 | |
(706) 228-7253 | |
Not Available |
News Archive
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.
Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.
In an ideal world, the newest and most effective drugs for chronic inflammatory conditions would immediately help everyone who took them.
› Verified 4 days ago
NPI Number | 1235370164 |
Organization Name | Rai-crossroads-augusta |
Doing Business As | Rai Care Centers Of Georgia I Llc |
Address | 1719 Magnolia Way Augusta, Georgia, 30909 |
Phone Number | (706) 228-7253 |
News Archive
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.
Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.
In an ideal world, the newest and most effective drugs for chronic inflammatory conditions would immediately help everyone who took them.
› Verified 4 days ago
Dialysis patients with Hemoglobin data | 16 |
News Archive
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.
Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.
In an ideal world, the newest and most effective drugs for chronic inflammatory conditions would immediately help everyone who took them.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 42 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 316 |
Percentage of adult patients getting regular hemodialysis at the center | |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.
Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.
In an ideal world, the newest and most effective drugs for chronic inflammatory conditions would immediately help everyone who took them.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Crossroads with elevated calcium levels.
Patients with hypercalcemia | 43 |
Hypercalcemia patient months | 328 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
Patients with Serumphosphor | 45 |
Patients with Serumphosphor less than 3.5 mg/dL | |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
Patients with Serumphosphor from 5.6 to 7 mg/dL | |
Patients with Serumphosphor greater than 7 mg/dL |
News Archive
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.
Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.
In an ideal world, the newest and most effective drugs for chronic inflammatory conditions would immediately help everyone who took them.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 39 |
Patient months included in arterial venous fistula and catheter summaries | 262 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.
Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.
In an ideal world, the newest and most effective drugs for chronic inflammatory conditions would immediately help everyone who took them.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | |
Hospitalization Rate in facility | (Not Available) |
Hospitalization Rate: Upper Confidence Limit | |
Hospitalization Rate: Lower Confidence Limit |
News Archive
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.
Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.
In an ideal world, the newest and most effective drugs for chronic inflammatory conditions would immediately help everyone who took them.
› Verified 4 days ago